Axogen Financials
AXGN Stock | USD 13.47 0.13 0.97% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.75 | 2.892 |
|
|
Investors should never underestimate Axogen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Axogen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Axogen Inc.
Net Income |
|
Axogen | Select Account or Indicator |
Understanding current and past Axogen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Axogen's financial statements are interrelated, with each one affecting the others. For example, an increase in Axogen's assets may result in an increase in income on the income statement.
Axogen Stock Summary
Axogen competes with Anika Therapeutics, Orthofix Medical, SurModics, Paragon 28, and Artivion. AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 428 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US05463X1063 |
CUSIP | 05463X106 523251106 |
Location | Florida; U.S.A |
Business Address | 13631 Progress Boulevard, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.axogeninc.com |
Phone | 386 462 6800 |
Currency | USD - US Dollar |
Axogen Key Financial Ratios
Return On Equity | -0.15 | ||||
Profit Margin | (0.08) % | ||||
Operating Margin | (0.01) % | ||||
Price To Sales | 3.25 X | ||||
Revenue | 159.01 M |
Axogen Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 154.6M | 201.4M | 208.0M | 195.4M | 196.8M | 206.7M | |
Other Current Liab | 10.9M | 16.5M | 16.5M | 13.5M | 17.1M | 18.0M | |
Net Debt | (32.4M) | 5.0M | 34.7M | 52.1M | 32.3M | 33.9M | |
Retained Earnings | (179.9M) | (203.6M) | (230.6M) | (259.6M) | (281.3M) | (267.2M) | |
Cash | 35.7M | 48.8M | 32.8M | 15.3M | 37.0M | 38.9M | |
Net Receivables | 16.9M | 17.6M | 18.2M | 22.2M | 25.1M | 26.4M | |
Inventory | 13.9M | 12.5M | 16.7M | 18.9M | 23.0M | 24.2M | |
Total Liab | 22.5M | 78.2M | 95.5M | 94.4M | 101.2M | 106.2M | |
Total Current Assets | 135.0M | 145.3M | 127.0M | 98.1M | 88.0M | 92.4M | |
Short Term Debt | 1.7M | 1.7M | 1.8M | 1.3M | 1.5M | 1.5M | |
Intangible Assets | 1.5M | 2.1M | 2.9M | 3.6M | 4.5M | 4.8M | |
Other Current Assets | 1.7M | 11.1M | 8.1M | 8.2M | 8.8M | 9.3M | |
Accounts Payable | 8.3M | 4.6M | 5.9M | 9.0M | 11.8M | 12.4M | |
Common Stock | 396K | 406K | 417K | 424K | 431K | 452.6K | |
Other Liab | 164K | 112K | 15K | 3K | 2.7K | 2.6K | |
Net Tangible Assets | 130.6M | 121.1M | 109.7M | 97.4M | 112.0M | 58.6M | |
Long Term Debt | 1.6M | 52.9M | 65.6M | 66.1M | 46.6M | 33.6M | |
Long Term Debt Total | 30K | 52.9M | 65.6M | 66.1M | 76.0M | 79.8M | |
Capital Surpluse | 311.6M | 326.4M | 342.8M | 360.2M | 414.2M | 210.4M | |
Short Long Term Debt | 4.7M | 28K | 1.7M | 863K | 776.7K | 737.9K |
Axogen Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 40K | 1.1M | 1.4M | 624K | 2.8M | 1.6M | |
Total Revenue | 106.7M | 112.3M | 127.4M | 138.6M | 159.0M | 167.0M | |
Gross Profit | 89.4M | 90.7M | 104.4M | 114.4M | 127.9M | 134.3M | |
Operating Income | (31.4M) | (23.2M) | (25.4M) | (29.7M) | (21.5M) | (20.4M) | |
Ebit | (31.4M) | (22.7M) | (25.6M) | (28.3M) | (18.9M) | (17.9M) | |
Ebitda | (26.2M) | (19.3M) | (20.9M) | (23.5M) | (13.3M) | (12.7M) | |
Cost Of Revenue | 17.3M | 21.6M | 22.9M | 24.1M | 31.1M | 32.7M | |
Income Before Tax | (29.1M) | (23.8M) | (27.0M) | (28.9M) | (21.7M) | (20.6M) | |
Net Income | (29.1M) | (24.8M) | (28.1M) | (27.3M) | (21.7M) | (20.6M) | |
Income Tax Expense | (13K) | 1.0M | 1.1M | (1.6M) | 5.4M | 5.7M | |
Research Development | 17.5M | 17.8M | 24.2M | 27.2M | 28.3M | 29.7M | |
Net Interest Income | (40K) | (1.1M) | (1.4M) | (624K) | (952K) | (999.6K) |
Axogen Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (3.8M) | (910K) | (7.5M) | (3.7M) | (6.1M) | (5.8M) | |
Change In Cash | 11.4M | 13.9M | (16.6M) | (17.5M) | 15.5M | 16.3M | |
Free Cash Flow | (141.5M) | (32.2M) | (41.8M) | (37.3M) | (20.6M) | (19.6M) | |
Depreciation | 2.9M | 3.5M | 4.7M | 4.9M | 5.6M | 5.8M | |
Other Non Cash Items | 2.5M | 232K | 831K | 2.0M | 6.9M | 7.3M | |
Capital Expenditures | 121.6M | 22.6M | 28.4M | 21.3M | 14.9M | 15.7M | |
Net Income | (29.1M) | (23.8M) | (27.0M) | (28.9M) | (21.7M) | (20.6M) | |
End Period Cash Flow | 41.7M | 55.6M | 39.0M | 21.5M | 37.0M | 38.9M | |
Net Borrowings | 29K | 35M | 15.0M | (12K) | (13.8K) | (13.1K) | |
Change To Netincome | 11.8M | 10.7M | 14.3M | 16.7M | 19.2M | 20.2M | |
Investments | 27.3M | 5.6M | 3.8M | 18.1M | 18.3M | 19.2M |
Axogen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Axogen's current stock value. Our valuation model uses many indicators to compare Axogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Axogen competition to find correlations between indicators driving Axogen's intrinsic value. More Info.Axogen Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Axogen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Axogen's earnings, one of the primary drivers of an investment's value.Axogen Inc Systematic Risk
Axogen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Axogen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Axogen Inc correlated with the market. If Beta is less than 0 Axogen generally moves in the opposite direction as compared to the market. If Axogen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Axogen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Axogen is generally in the same direction as the market. If Beta > 1 Axogen moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Axogen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Axogen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Axogen growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Axogen November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Axogen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Axogen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Axogen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Axogen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Axogen's daily price indicators and compare them against related drivers.
Downside Deviation | 4.08 | |||
Information Ratio | 0.0129 | |||
Maximum Drawdown | 21.6 | |||
Value At Risk | (5.50) | |||
Potential Upside | 4.73 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axogen. If investors know Axogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Revenue Per Share 4.16 | Quarterly Revenue Growth 0.179 | Return On Assets (0.03) | Return On Equity (0.15) |
The market value of Axogen Inc is measured differently than its book value, which is the value of Axogen that is recorded on the company's balance sheet. Investors also form their own opinion of Axogen's value that differs from its market value or its book value, called intrinsic value, which is Axogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axogen's market value can be influenced by many factors that don't directly affect Axogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.